ClinicalTrials.gg

Program

IEV407

A development code.

Its studies are mostly in Breast Neoplasms, led by Novartis.

Furthest: phase 1, since May 18, 20261 company-led study, 1 open or runningNext primary completion: Jun 8, 2032 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 1since May 18, 2026May 18, 2026Jun 8, 2032phase 1 · NCT07604571
  • Named in Novartis’s own pipeline as IEV407, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2026First study: phase 1 study in Advanced HR+/HER2- Breast CancerFirst studyNCT07604571 · 194 planned · United States, Canada, France and more

Ahead

  1. Jun 8, 2032Primary completion: phase 1 study in Advanced HR+/HER2- Breast CancerNCT07604571

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07604571Advanced HR+/HER2- Breast Cancer · United States, Canada, France and more1RecruitingJun 8, 2032194

How it is read

Names in the registry

  • “IEV407”, 1 entry

Codes read as this program: IEV407.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.